Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients

Key Takeaways

• Health Canada approved Fabhalta (iptacopan) as first oral Factor B inhibitor for treating C3G in adults
• Phase III trial showed clinically meaningful reduction in proteinuria at 6 months with sustained effects through 12 months
• Approval provides new treatment option for patients with this rare kidney disease that can lead to kidney failure

---

Novartis announced on May 1, 2026, that Health Canada has approved Fabhalta® (iptacopan capsules) for treating adults with complement 3 glomerulopathy (C3G), marking a significant milestone for patients with this rare kidney disease.

Breakthrough Treatment for Rare Kidney Disease

Fabhalta is an oral Factor B inhibitor specifically indicated to reduce proteinuria in adult patients with C3G. This approval represents the first targeted oral therapy for this rare complement-mediated kidney disease that affects the glomeruli, the filtering units of the kidneys.

C3G is a progressive kidney disease caused by dysregulation of the complement system, leading to abnormal protein deposits in the kidneys. Without effective treatment, the condition often progresses to end-stage renal disease requiring dialysis or kidney transplantation.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Strong Clinical Trial Results

The approval is based on results from the Phase III APPEAR-C3G study, which demonstrated Fabhalta’s efficacy in reducing proteinuria—excess protein in urine that indicates kidney damage. The trial showed clinically meaningful and statistically significant proteinuria reduction at six months, with benefits sustained through 12 months of treatment.

This sustained improvement is particularly important for C3G patients, as proteinuria reduction correlates with slowed disease progression and preserved kidney function over time.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Patient Access

The Health Canada approval expands Fabhalta’s global regulatory footprint and provides Canadian patients access to this innovative therapy. As an oral treatment, Fabhalta offers convenience compared to injectable alternatives, potentially improving patient compliance and quality of life.

For Novartis, this approval strengthens its nephrology portfolio and reinforces its commitment to rare disease treatments. The company continues seeking regulatory approvals in other markets to broaden patient access worldwide.

---

Frequently Asked Questions

What is C3G and how does Fabhalta help?

C3G is a rare kidney disease caused by complement system dysfunction. Fabhalta works as a Factor B inhibitor to block abnormal complement activation, reducing protein loss in urine and slowing kidney damage progression.

When will Fabhalta be available to Canadian patients?

Following Health Canada approval, Novartis will work on commercial launch logistics including pricing negotiations and distribution. Patients should consult their nephrologists about access timelines and eligibility.

How does Fabhalta compare to existing C3G treatments?

Fabhalta represents the first targeted oral therapy specifically approved for C3G. Previously, treatment options were limited to supportive care and off-label immunosuppressive therapies with variable effectiveness.

Related coverage

• Vabysmo gains EU approval for retinal vein occlusion: what changes next
• Novartis remibrutinib wins Phase 3 in CSU: what it means
• Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria